Experimental hepatitis b drug shows promise in early trial

NCT ID NCT02604199

Terminated Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tested an experimental drug called ARC-520 in 58 people with chronic hepatitis B who were already taking standard antivirals. The goal was to see if ARC-520 could further lower hepatitis B surface antigen levels, a marker of the virus. The study was terminated early, so final results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARC-520 (an experimental RNA interference drug)
What this could lead to: If successful, ARC-520 could help control hepatitis B more effectively by reducing viral proteins, potentially lowering the risk of liver damage.
What could go wrong: This was an early Phase 2 trial that was terminated, so results are limited. The drug may not work as hoped, and side effects are possible. Patients still need lifelong antiviral medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B

Contacts and locations

Locations

Research Site 1

Hong Kong, 999077, China
Research Site 10

Leipzig, 04103, Germany
Research Site 11

Frankfurt, 60590, Germany
Research Site 12

Yangsan-si Gyeongnam, 626-770, South Korea
Research Site 13

Busan, 602-739, South Korea
Research Site 14

Seoul, 110-744, South Korea
Research Site 15

Incheon, 405-760, South Korea
Research Site 16

Seoul, 120-752, South Korea
Research Site 2

Hong Kong, China
Research Site 3

Tübingen, 72076, Germany
Research Site 4

Leipzig, 4103, Germany
Research Site 5

München, 81377, Germany
Research Site 6

Ulm, 89081, Germany
Research Site 7

Würzburg, 97080, Germany
Research Site 8

Hanover, 30625, Germany
Research Site 9

Hamburg, 20099, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.